Please assess the completion status of the following clinical trial:

Trial Title: Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Group 1 :~* Patient over 18 years old,~* Patient informed and not opposed to participate~* Patient followed for an autoimmune or inflammatory disease (vasculitis, systemic lupus, systemic sclerosis, non-infectious uveitis)~* Treatment with immunosuppressant and / or immunomodulator~* Group 2 :~* Patient over 18 years old,~* Patient informed and not opposed to participate~* Patient not followed for an autoimmune or inflammatory disease (vasculitis, systemic lupus, systemic sclerosis, non-infectious uveitis)~* Absence of treatment with immunosuppressant and / or immunomodulator~Exclusion Criteria:~* Contraindication to vaccination~* Progressive cancer~* Pregnant or breastfeeding woman~* Current infection less than 3 weeks old~* Weight less than 40 kg~* Patient under tutor- or curator-ship~* Patient without health insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with auto-immune or autoinflammatory diseases (Type: None): Patients with auto-immune or autoinflammatory diseases treated with immunosuppressants and/or biologics
- Patients without auto-immune or autoinflammatory diseases (Type: None): Patients without auto-immune or autoinflammatory diseases and not treated with immunosuppressants and/or biologics

Based on this trial design, predict the completion outcome and termination type (if applicable).